Alleviation of Ultraviolet-B Radiation-Induced Photoaging by a TNFR Antagonistic Peptide, TNFR2-SKE.


Journal

Molecules and cells
ISSN: 0219-1032
Titre abrégé: Mol Cells
Pays: Korea (South)
ID NLM: 9610936

Informations de publication

Date de publication:
28 Feb 2019
Historique:
received: 08 11 2018
revised: 13 12 2018
accepted: 01 01 2019
pubmed: 2 2 2019
medline: 23 4 2019
entrez: 2 2 2019
Statut: ppublish

Résumé

Ultraviolet (UV) radiation of the sunlight, especially UVA and UVB, is the primary environmental cause of skin damage, including topical inflammation, premature skin aging, and skin cancer. Previous reports show that activation of nuclear factor-κB (NF-κB) in human skin fibroblasts and keratinocytes after UV exposure induces the expression and release of proinflammatory cytokines, such as interleukin-1 (IL-1) and tumor necrosis factor-α (TNF-α), and subsequently leads to the production of matrix metalloproteases (MMPs) and growth factor basic fibroblast growth factor (bFGF). Here, we demonstrated that TNFR2-SKEE and TNFR2-SKE, oligopeptides from TNF receptor-associated factor 2 (TRAF2)-binding site of TNF receptor 2 (TNFR2), strongly inhibited the interaction of TNFR1 as well as TNFR2 with TRAF2. In particular, TNFR2-SKE suppressed UVB- or TNF-α-induced nuclear translocalization of activated NF-κB in mouse fibroblasts. It decreased the expression of bFGF, MMPs, and COX2, which were upregulated by TNF-α, and increased procollagen production, which was reduced by TNF-α. Furthermore, TNFR2-SKE inhibited the UVB-induced proliferation of keratinocytes and melanocytes in the mouse skin and the infiltration of immune cells into inflamed tissues. These results suggest that TNFR2-SKE may possess the clinical potency to alleviate UV-induced photoaging in human skin.

Identifiants

pubmed: 30703869
pii: molcells.2018.0423
doi: 10.14348/molcells.2018.0423
pmc: PMC6399009
doi:

Substances chimiques

NF-kappa B 0
Peptides 0
Receptors, Tumor Necrosis Factor, Type I 0
Receptors, Tumor Necrosis Factor, Type II 0
TNF Receptor-Associated Factor 2 0
Tumor Necrosis Factor-alpha 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

151-160

Références

Mol Cell. 1999 Sep;4(3):321-30
pubmed: 10518213
Exp Dermatol. 2000 Jun;9(3):165-9
pubmed: 10839713
J Cell Sci. 2001 Jan;114(Pt 1):131-139
pubmed: 11112697
Am J Pathol. 2001 Mar;158(3):943-53
pubmed: 11238042
Oncogene. 2001 Oct 1;20(44):6482-91
pubmed: 11607847
J Cell Sci. 2002 Feb 15;115(Pt 4):679-88
pubmed: 11865024
Arch Dermatol Res. 2002 Jan;293(11):576-83
pubmed: 11876526
Front Biosci. 2002 Aug 01;7:a169-74
pubmed: 12133815
Pigment Cell Res. 2002 Oct;15(5):391-9
pubmed: 12213097
J Biol Chem. 2003 Aug 1;278(31):29216-30
pubmed: 12709429
Cell. 2004 Feb 20;116(4):491-7
pubmed: 14980217
Cutis. 2005 Feb;75(2 Suppl):5-8; discussion 8-9
pubmed: 15773537
J Pharmacol Exp Ther. 2005 Nov;315(2):624-30
pubmed: 16027228
Int J Mol Med. 2005 Nov;16(5):943-50
pubmed: 16211268
Mol Cell Biol. 2005 Nov;25(22):9806-19
pubmed: 16260598
Photochem Photobiol Sci. 2006 Feb;5(2):184-9
pubmed: 16465304
Clin Oncol (R Coll Radiol). 2007 Mar;19(2):154-61
pubmed: 17355113
J Biol Chem. 2007 May 18;282(20):14788-96
pubmed: 17389591
Mol Cell. 2008 Jun 6;30(5):632-41
pubmed: 18538661
Arch Dermatol Res. 2009 Jan;301(1):87-91
pubmed: 18825399
J Invest Dermatol. 2009 Apr;129(4):994-1001
pubmed: 19005488
BMC Immunol. 2009 Mar 19;10:15
pubmed: 19298660
Nat Rev Drug Discov. 2010 Jun;9(6):482-93
pubmed: 20489699
Curr Drug Metab. 2010 Jun 1;11(5):431-5
pubmed: 20540695
FEBS J. 2011 Apr;278(6):888-98
pubmed: 21232019
J Immunol. 2011 Aug 1;187(3):1289-97
pubmed: 21724995
J Inflamm (Lond). 2012 Oct 05;9(1):38
pubmed: 23039818
ISRN Dermatol. 2013 Sep 12;2013:930164
pubmed: 24159392
PLoS One. 2013 Dec 05;8(12):e82282
pubmed: 24340014
J Immunol. 2015 Jun 1;194(11):5094-102
pubmed: 25911755
Asian Pac J Cancer Prev. 2015;16(18):8411-8
pubmed: 26745094
Antioxidants (Basel). 2015 Mar 26;4(2):248-68
pubmed: 26783703
Biochem Pharmacol. 2016 Sep 15;116:1-10
pubmed: 26993379
Mol Cells. 2016 Jul;39(7):557-65
pubmed: 27306643
PLoS One. 2017 Mar 16;12(3):e0174042
pubmed: 28301572
Mol Cells. 2018 Aug 31;41(8):753-761
pubmed: 30037215
Cell. 1994 Aug 26;78(4):681-92
pubmed: 8069916
J Invest Dermatol. 1994 Apr;102(4):422-7
pubmed: 8151120
Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8241-6
pubmed: 8710854
Biochem Biophys Res Commun. 1997 Apr 28;233(3):592-600
pubmed: 9168896
Br J Dermatol. 1998 Feb;138(2):216-20
pubmed: 9602863
J Immunol. 1998 Jul 1;161(1):390-9
pubmed: 9647248
FEBS Lett. 1998 Sep 11;435(1):29-34
pubmed: 9755853
J Invest Dermatol. 1998 Nov;111(5):864-72
pubmed: 9804351
Free Radic Biol Med. 1999 Jan;26(1-2):174-83
pubmed: 9890652

Auteurs

Kyoung-Jin Lee (KJ)

Department of Anatomy and Cell Biology, School of Medicine, Kangwon National University, Chuncheon 24341, Korea.

Kyeong Han Park (KH)

Department of Anatomy and Cell Biology, School of Medicine, Kangwon National University, Chuncheon 24341, Korea.

Jang-Hee Hahn (JH)

Department of Anatomy and Cell Biology, School of Medicine, Kangwon National University, Chuncheon 24341, Korea.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH